Abstract: A system for submitting a claim for a dispensed medication to a patient by a point-of-care physician including means acquiring at least one of the group consisting of a national practitioner number and a non pharmacy dispensing number for the point-of-care physician; means for displaying to a user a selection of data fields relating to the claim; means for inputting into the data fields data relating to the claim including the at least one of the group consisting of the national practitioner identifier number and the non pharmacy dispensing number; means for transmitting to a logic switch the claim containing the at least one of the group consisting of a national practitioner identifier number and a non pharmacy dispensing number identifying the point-of-care physician for determining the processor for the claim; means for determining the pathway for the claim based on a type of payor associated with the patient; means for processing the claim containing the at least one of the group consisting of a national

Abstract: A method for submitting a claim form for a dispensed medication to a patient by a point-of-care physician including determining the dispensed medication and payor for the patient by the point-of-care physician; acquiring a national provider identifier number and a non-pharmacy dispensing number for the point-of-care physician; displaying to a user a selection of data fields to the claim form; inputting into the data fields data relating to the claim including the payor and at least one of the national provider identifier number and the non-pharmacy dispensing number; transmitting to a logic switch the claim form including the payor and the at least one of the national provider identifier number and the non-pharmacy dispensing number identifying the point-of-care physician for determining the processor for the claim form; determining the pathway for the claim form based on the payor; processing the claim form by the payor; and transmitting an adjudication.

Abstract: The methods and compositions for potentiating pharmaceuticals with amino acid based medical foods provides improved cognitive function; induced and maintained sleep; reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, and appetite; and treated depression. The amino acid based medical foods, co-packed with at least one selected pharmaceutical, potentiate the pharmaceutical by enhancing the production of neurotransmitters through the oral administration of neurotransmitter precursors, along with natural plant and animal substances that stimulate uptake of the neurotransmitter precursors, cause release of neurotransmitters, cause disinhibition of the neuronal brake, and activate adenylate cyclase in order to avoid tachyphylaxis and prevent pharmacologic tolerance.

Abstract: A system for submitting a claim for a dispensed medication to a patient by a point-of-care physician including means acquiring at least one of the group consisting of a national practitioner number and a non pharmacy dispensing number for the point-of-care physician; means for displaying to a user a selection of data fields relating to the claim; means for inputting into the data fields data relating to the claim including the at least one of the group consisting of the national practitioner identifier number and the non pharmacy dispensing number; means for transmitting to a logic switch the claim containing the at least one of the group consisting of a national practitioner identifier number and a non pharmacy dispensing number identifying the point-of-care physician for determining the processor for the claim; means for determining the pathway for the claim based on a type of payor associated with the patient; means for processing the claim containing the at least one of the group consisting of a national

Abstract: The invention relates to an inexpensive and easy to use method of visualizing an arterial circulation, using biodegradable microspheres which are permeated with an imaging energy absorbent contrast material, such as an X-ray absorbent material, which enables the diagnosis of pulmonary embolism. The microspheres may be comprised of a variety of materials, including human albumin, and may be dyed with a number of X-ray absorbent materials, or other imaging energy absorbent materials. The microspheres are injected into the bloodstream at a particular location such that they travel through the desired circulation, e.g. an arterial circulation and ultimately become lodged in the capillaries of a tissue of interest. Upon exposure of the arterial circulation to X-rays, blood vessels therein containing the microspheres will absorb the X-rays, causing them to show on a developed X-ray film in contrast to other blood vessels and body tissue which do not contain the microspheres that transmit the X-rays.

Abstract: A kit for preventing or treating arterial dysfunction resulting from an angioplasty procedure and particularly, in myocardial angioplasty procedures in human beings. The kit provides the materials necessary to introduce a selected amount of an intraarterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur and an intravenous prostaglandin compound. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. A composition is also provided for reducing dysfunction in angioplasty procedures and comprises a selected amount of a carrier and a prostaglandin compound carried in a specified amount and which carrier does not alter the prostaglandin compound and releases the prostaglandin compound at a rate sufficient to dilate blood vessels to thereby produce the required efficacy.

Abstract: A method and a composition for accumulating and the binding of food fats in an animal body gastrointestinal tract. The method and composition rely upon non-biodegradable collagen particles, such as microspheres, having a size of at least two microns and a fat receptor, such as bile, capable of having food fat adhered thereto on the surface of the particles. These particles are sufficiently large so that they do not pass through the surface mucosa of the gastrointestinal tract and permit the particles with the food fat to pass through the gastrointestinal tract and out of the body through animal excretion.

Abstract: A method for reducing dysfunction in angioplasty procedures and particularly, in myocardial angioplasty procedures in human beings is desired. The method involves the introduction of a selected amount of intra-arterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. The prostaglandin compound is administered in a pharmacological amount, that is, an amount substantially greater than the prostaglandin which would be generated by a normal myocardial artery when insulated and thus, constitutes an administration substantially greater than an amount which would be administered in a replacement therapy.

Abstract: A process for making a volumetric determination of the quantity of a fluid, such as a liquid, by evaluation of a small sample of that fluid. The method comprises labeling microspheres with a non-radioactive substance and introducing the labeled microspheres into a body of fluid for which a determination is to be made. The microspheres are allowed to disperse in the body of fluid. Thereafter, a sample of the fluid which is of know or measurable volume, is selected. The number of microspheres present in the sample is then determined, from which a calculation of the volumetric measurement of the fluid may be made. The process is also adaptable to measuring the flow rate of a moving stream of fluid, since volume is one of the parameters of flow rate, and is also adaptable to determine the percentages of fluid components present in a mixture thereof.

Abstract: A method and means for determining the risk of future cardiac ischemic events in a patient after a sentinel event in that same patient, wherein levels of acid glycoprotein and CK-MB are monitored relative to predetermined threshold levels, within a prescribed time frame after the sentinel event, and these monitored levels are then correlated with the predicted likelihood of future cardiac ischemic events to classify such cardiac patients into categories of risk.